Objectives: Bactericidal activity depends on antibiotic-bacteria couples, resistance phenotype and theoretically on protein binding. This work explores the influence of protein binding on the bactericidal activity of two antibiotics, daptomycin versus vancomycin, that exhibit, respectively, different C max (56 versus 25.5 mg/L), protein binding (91.7% versus 36.9%) and thus theoretical free-drug fractions (4.7 versus 16.1 mg/L).
Introduction
Problems in Gram-positive bacteria are the established penicillin/ macrolide/quinolone resistance in Streptococcus pneumoniae, 1 the increasing methicillin resistance in Staphylococcus aureus 2 and the emerging vancomycin resistance in S. aureus and Enterococcus faecium, 3 in Spain. Glycopeptides, especially vancomycin, are the main weapon against Gram-positive serious infections caused by multidrugresistant S. pneumoniae and methicillin-resistant S. aureus (MRSA). The possibility of vancomycin resistance has led to the development of newer agents such as the lipopeptide daptomycin that exhibits greater bactericidal activity. However, its high protein binding means that the influence of the binding on its bactericidal activity deserves to be studied.
This study tries to explore the in vitro effect of the presence of physiological concentrations of human albumin or very high concentrations of human serum on the bactericidal activity of peak concentrations (versus the theoretical free-drug peak concentration) of daptomycin (a drug with high protein binding and thus a low free-drug fraction) versus vancomycin (a drug with low protein binding).
Materials and methods

Strains
Three amoxicillin-resistant (MIC ! 8 mg/L) S. pneumoniae strains [one serotype 14 susceptible to levofloxacin and one serotype 14 and one serotype 9V both resistant to levofloxacin (MICs ¼ 16 mg/ L)], three S. aureus strains [one methicillin-susceptible, one MRSA (cloxacillin MIC ! 128 mg/L) and one MRSA heterogeneous vancomycin-intermediate (MRSA-hVI)] and two E. faecium strains (one vancomycin-susceptible and one vancomycin-resistant) were used throughout the study. MICs of daptomycin and vancomycin were determined five times following CLSI (formerly NCCLS) recommendations 4 and modal values were considered. The test medium was cation-adjusted Mueller -Hinton broth, supplemented with calcium to a target level of 50 mg/L as suggested by the CLSI. 4 Vancomycin heteroresistance in S. aureus was determined as described previously. 5 
Killing curves
Killing curves were performed with final inocula of $10 7 cfu/mL and a final concentration of daptomycin or vancomycin of 56 or 25.5 mg/L, corresponding to C max concentrations after an intravenous dose of 4 mg/kg daptomycin and 1 g of vancomycin, 6, 7 respectively. Different media were used: (i) Mueller -Hinton broth (Difco, Detroit, MI, USA) with 5% lysed horse blood (Biomedics, Madrid, Spain) for S. pneumoniae or without blood supplement for S. aureus and E. faecium (C max -MH); (ii) Mueller -Hinton broth with a final human serum (S-7023; Sigma Aldrich, St Louis, MO, USA) concentration of 90% (C max -HS); and (iii) Mueller -Hinton broth with 4 g/dL human albumin (A-1653; Sigma Aldrich) (C max -HAlb). In parallel, killing curves with concentrations corresponding to free-drug C max when considering protein binding (91.7% for daptomycin 6 and 36.9% for vancomycin 7 ), i.e. 4.7 and 16.1 mg/L, respectively, were performed in Mueller -Hinton broth (8.3% C max for daptomycin and 63.1% C max for vancomycin). Mueller -Hinton broth was supplemented with 50 mg of Ca 2þ per litre according to CLSI recommendations for daptomycin, 4 except in tubes with human albumin where 100 mg of Ca 2þ per litre was added to obtain a physiological free Ca 2þ concentration. 8 Control growth curves in the absence of antibiotics were performed in all tested media. Samples for colony counting were collected at 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24 h. All experiments were performed in triplicate. The limit of detection was 5 Â 10 2 cfu/mL. Bactericidal activity was defined as !3 log 10 reduction of initial inocula.
Statistical analysis
Log 10 reductions (log 10 colony counts at time 0-log 10 colony counts at each sampling time) at 24 h using free-drug concentrations (8.3% C max for daptomycin and 63.1% C max for vancomycin) were compared with those obtained with the C max in the different media, and differences were determined by the Student's t-test. Differences between log 10 reductions obtained with the C max in different media for each strain were determined by ANOVA with the Tukey test for multiple comparisons. P , 0.001 was considered statistically significant.
Results
Final log 10 counts at 24 h in antibiotic-free controls ranged from 8.0 to 9.0 log 10 for S. pneumoniae and S. aureus and from 7.2 to 8.6 log 10 for E. faecium regardless of the media used. Table 1 shows the MICs of daptomycin and vancomycin for the study strains and time (in hours) to obtain bactericidal activity (!3 log 10 reduction in initial inocula) in the different media tested. Figures 1 and 2 show killing curves for S. pneumoniae and S. aureus (mean + SD colony counts over 24 h). Daptomycin exhibited very high and rapid bactericidal activity (within the first 4 h for all strains tested) against S. pneumoniae regardless of the media used or when the concentration similar to that of the free-drug fraction was tested. This was not the case for vancomycin, with much longer times (10-24 h) for bactericidal activity against all strains.
Against S. aureus, regardless of the strain tested, daptomycin was also rapidly bactericidal ( 4 h). Against MRSA-hVI, bactericidal activity was delayed from 2 to 3 h in the presence of human serum and to 4 h in the presence of human albumin [the same time for bactericidal activity with the free-drug concentration (8.3% C max )]. Vancomycin exhibited bactericidal activity at 24 h against the two vancomycin-susceptible S. aureus strains, but not against the MRSA-hVI strain where 2 log 10 reduction was obtained at 12 -24 h in the presence of serum. Figure 3 shows mean + SD colony counts of E. faecium in the different media with daptomycin and vancomycin over 24 h. No significant initial inocula decrease was obtained with vancomycin against both strains, regardless of vancomycin susceptibility.
Daptomycin C max in Mueller -Hinton broth with or without 4 g/dL albumin showed bactericidal activity against the two strains at 24 h, with significantly (P , 0.001) lower log 10 reductions for 8.3% C max daptomycin. Differences between 8.3% C max and C max -HS did not reach statistical significance, although a tendency is clearly observed (P ¼ 0.0048). Against the vancomycin-resistant strain, differences were also significant when comparing log 10 reductions with C max -MH versus C max -HS or C max -MH versus C max -HAlb, and between C max -HS and C max -HAlb. Albumin delayed the daptomycin bactericidal activity from 2 to 8 h for the vancomycin-susceptible strain and from 2 to 24 h for the vancomycin-resistant strain, although 2.8 log 10 reductions were obtained from 10 h onwards.
Discussion
Bactericidal activity depends on antibiotic -bacteria couples, resistance phenotype and theoretically on the antibiotic protein binding rate, since classically it has been considered that only free-drug (extrapolated from total drug by using the protein binding rate) exerts antibacterial activity. Nevertheless, the quick reversibility of protein binding implies that limitation of activity may be far from absolute, even in highly protein-bound agents. 9 For this reason, we have studied the effect of the resistance phenotype and the presence of physiological concentrations of human albumin or human serum on the bactericidal activity of daptomycin versus vancomycin against the three main Gram-positive pathogens.
When MICs are very low, as in the case of daptomycin for S. pneumoniae, bactericidal activity is exerted at very short times regardless of the presence of 90% human serum or physiological concentrations of human albumin, or even when the concentration in Mueller -Hinton broth is similar to that of the free-drug fraction. The presence of serum or albumin may delay total daptomycin C max bactericidal activity for a few hours, but always for a time shorter than the dosing interval (12 h). This is not the case for vancomycin, which exhibited a much lower intrinsic activity. In the presence of human serum, vancomycin only exhibited bactericidal activity at 24 h, a time longer than the dosing interval.
Against S. aureus, daptomycin and vancomycin exhibited results similar to those obtained against S. pneumoniae (rapid bactericidal activity of daptomycin and slow bactericidal activity of vancomycin) except in the case of vancomycin against MRSA-hVI where vancomycin never exhibited bactericidal activity, whereas daptomycin exhibited bactericidal activity at a very short time (as with the other strains).
With regard to enterococci, there was an absence of decrease in initial inocula with vancomycin for 24 h even against the vancomycin-susceptible strain. In contrast, daptomycin offers early (at 2 h) bactericidal activity against the two strains that is delayed to 8 h against the vancomycin-susceptible strain and to 24 h against the vancomycin-resistant strain by albumin, whereas no bactericidal activity is exerted by the free-drug concentration in Mueller-Hinton. Thus, extrapolation of active drug from total drug by using the protein binding rate does not seem an accurate method to study antibacterial activity considering the implications of protein binding.
The daptomycin C max value (56 mg/L) considered in this in vitro study corresponds to a 4 mg/kg dose, 6 the dose approved by the FDA for the treatment of skin and soft tissue infections. Recently, a dose of 6 mg/kg, attaining a serum concentration of 95.7 mg/L, 10 has been approved for the treatment of bacteraemia or endocarditis. The significant delay due to albumin in the time to obtain bactericidal activity against E. faecium in this study may be minimized using that concentration of daptomycin.
In conclusion, daptomycin exhibited very rapid bactericidal activity against the strains of the three Gram-positive species tested regardless of resistance phenotype, with slight delays in the presence of albumin or human serum against S. pneumoniae and S. aureus and longer delays in the case of E. faecium. Since bactericidal activity may be essential in severe patients, nowadays the use of vancomycin that exhibits very slow bactericidal activity against S. pneumoniae and vancomycin-susceptible S. aureus and the absence of bactericidal activity against vancomycin-resistant S. aureus or vancomycin-susceptible or -resistant E. faecium may be a matter of debate.
